A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy

A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy

Abstract Background The effective treatment of triple-negative breast cancer (TNBC) remains a profound clinical challenge. Despite frequent epidermal growth factor receptor (EGFR) overexpression and reliance on downstream signalling pathways in TNBC, resistance to EGFR-tyrosine kinase inhibitors (TK...

Full description

Bibliographic Details
Main Authors: Ronan P. McLaughlin, Jichao He, Vera E. van der Noord, Jevin Redel, John A. Foekens, John W. M. Martens, Marcel Smid, Yinghui Zhang, Bob van de Water
Format: Article
Language:English
Published: BMC 2019-07-01
Series:Breast Cancer Research
Subjects:
CDK9/Cdc7 inhibition
EGFR-targeted therapy
Drug resistance
Triple-negative breast cancer
Online Access:http://link.springer.com/article/10.1186/s13058-019-1161-9

Internet

http://link.springer.com/article/10.1186/s13058-019-1161-9

Similar Items